已毕业博士生，获得国家自然科学基金青年基金项目2项。

1. 国家自然科学基金面上项目 （82170541） Glcα1,2Galβ1-糖基化修饰: IL-2/IL-2R介导JAK-STAT信号途径激活的关键？2022.01- 2025.12  

2. 国家自然科学基金面上项目（81271901）乙肝病毒颗粒组装的质量控制：aer61辅助糖型分选 2013.1-2016.12

3. 国家自然科学基金面上项目（81071411）糖基因C3orf39:肝星状细胞增殖调控的新靶点？ 2011.1-2013.12

4. 国家自然科学基金面上项目（30872243） 新糖基因Glt25D2克隆及在HBV糖基化修饰过程中的作用研究2009.1-2011.12

5. 国家自然科学基金面上项目（30671875） 肝星状细胞血管紧张素II功能相关新基因的克隆表达及功能研究 2007.1-2009.12

6. 国家重点研发计划项目子课题（2018YFC1705700） ：茵芪三黄解毒汤治疗乙肝相关性代偿期肝硬化的临床研究 2018.12-2021.12

7. 北京市自然科学基金 （7202071）GlCα1，2Galβ1糖基化修饰对CD4+T细胞亚群增殖的影响及在肝损伤中的作用 2020.1-2022.12

8. 北京市医院管理中心消化内科学科协同发展中心专项（XXZ04）：食管胃静脉曲张出血风险评价算法的建立及应用 2018.06-2022.06 

9. 北京市自然科学基金（7152073） GlCα1，2Galβ1糖基化修饰对肝细胞脂肪变代谢调控的分子机制研究 2015.1-2017.12

10.  首都临床特色应用研究（Z181100001718084）GP73对NASH的临床诊断价值研究 2018.06-2021.05

11. 首都临床特色应用研究（Z141107002514132）GP73对HBV相关早期肝癌的预警诊断价值研究  2014.06-2017.06 

12.  首都卫生发展科研专项项目（2014-2-2171）：慢性HBV感染肝纤维化分期诊断新算法模型的建立及应用 2014.06-2017.05 

所带领的课题组先后获得国家自然科学基金面上项目资助8项；北京市自然科学基金面上项目2项；首都临床特色研究项目2项；首都医学发展基金1项；其他横、纵向课题10余项。

获得国家发明专利2项；PCT专利2项。主要通讯作者SCI论文列表。

1.      Song A, Mao Y, Wei H. GLUT5:structure, functions, diseases and potential applications. Acta Biochim BiophysSin (Shanghai). 2023 Oct 25;55(10):1519-1538.

2.      An W, Luo J, Yu Z, Li M, Wei H,Song A, Mao Y, Bian H, He L, Xiao F, Wei H. Obesity and risk for liver disease:a two-sample Mendelian randomisation study. Br J Nutr. 2024 Nov28;132(10):1403-1410. 

3.      Wei H, Gao M, Wang S, Yang J,Yu Z, Li M, Wei H, Xiao F. FAM172A deletion aggravates high fat diet-inducedMASLD via the eIF2α-ATF4-FGF21 loop. Life Sci. 2025 Sep 1;376:123763. 

4.      Yu Z, Luo J, An W, Wei H, SongA, Mao Y, Li M, He L, Xiao F, Gao Q, Wei H. EOGT knockdown promotes ferroptosisand inhibits hepatocellular carcinoma proliferation by regulating SLC7A11 viaHEY1. Cell Signal. 2025 Aug;132:111772. 

5.      Wang Z, Tan W, Xiong H, HuangJ, Wei H, Li M, Luo J, An W, He L, Ma J, Xiao F, Wei H. Impact of Helicobacterpylori infection on iron deficiency anemia in children: a systematicreview and meta-analysis with early intervention implications. Front Microbiol.2025 Jun 19;16:1541011.

6.      Hong S, Sun L, Hao Y, Li P,Zhou Y, Liang X, Hu J, Wei H. From NAFLD to MASLD: When metabolic comorbiditymatters. Ann Hepatol. 2024 Mar-Apr;29(2):101281. 

7.      Wang Z, Tan W, Wu L, Zhang P,Xiong H, Zhu L, Huang J, Cui J, Li L, Guo C, He L, Wei H, Liu H. Bacteroides,Metabolites, and Lymphocytes: A Triad of Biomarkers in Small IntestinalBacterial Overgrowth. Food Sci Nutr. 2025 Jun 20;13(6):e70367. 

8.      Yu Z, Luo J, An W, Wei H, Li M,He L, Xiao F, Wei H. Migrasome Marker Epidermal Growth FactorDomain-Specific O-GlcNAc Transferase: Pan-Cancer AngiogenesisBiomarker and the Potential Role of circ_0058189/miR-130a-3p/EOGT Axis inHepatocellular Carcinoma Progression and Sorafenib Resistance. Biomedicines.2025 Mar 22;13(4):773.

9.      Luo J, Yu Z, An W, Li M, Wei H,Wang Z, He L, Xiao F, Wei H. Tubuloside B alleviates con A-induced acute liverinjury by inhibiting the IL-23/JAK2/STAT3 signaling pathway hyperactivationduring Th17 cell differentiation. Int Immunopharmacol. 2025 Dec 3;166:115586. 

10.    Wang S, He L, Xiao F, Gao M,Wei H, Yang J, Shu Y, Zhang F, Ye X, Li P, Hao X, Zhou X, Wei H. Upregulationof GLT25D1 in Hepatic Stellate Cells Promotes Liver Fibrosis via theTGF-β1/SMAD3 Pathway In Vivo and In vitro. J ClinTransl Hepatol. 2023 Feb 28;11(1):1-14. 

11.    Wei H, Zhang Y, Gao M, Yang J,Wang S, Zhou X, Wei H, Xiao F. Loss of FAM172A gene prompts cell proliferationin liver regeneration. Mol Cell Biochem. 2025 Feb;480(2):1183-1195. 

12.    Ye X, He L, Deng C, Yang J, LiP, Wei H. Noninvasive elastography-based assessment of liver fibrosis inprimary biliary cholangitis. Ann Hepatol. 2025 Oct 26;31(1):102150.

13.    Hong S, Liu Z, Li P, Zhang J,Wei H. Golgi protein 73: charting new territories in diagnosing significantfibrosis in MASLD: a prospective cross-sectional study. Front Endocrinol(Lausanne). 2025 Jan 13;15:1506953.

14.    An W, Li M, Luo J, Yu Z, Wei H.Prognosis of Acute HEV Infection in Patients With Liver Cirrhosis: ARetrospective Study of 628 Chinese Patients. J Viral Hepat. 2025Apr;32(4):e14018. 

15.    Hong S, Hao Y, Sun L, Li P,Yang J, Zhang F, He L, Zhang J, Wei H. Prevalence and risk factors ofsignificant fibrosis in chronic hepatitis B patients with concurrent metabolicdysfunction-associated steatotic liver disease. Ann Hepatol. 2025 Jul-Dec;30(2):101589. 

16. Shu Y, He L, Gao M, Xiao F,YangJ, Wang S, Wei H, Zhang F, Wei H. EOGT Correlated With ImmuneInfiltration: ACandidate Prognostic Biomarker for Hepatocellular Carcinoma.  FrontImmunol. 2022;12:780509.

17. Ma JL, Li P, Jiang L, Wei HS.Long-termoutcomes of hepatectomy or radiofrequency ablation associated withsplenectomyfor the treatment of hepatocellular carcinoma and esophagogastricvaricealbleeding. Asian J Surg. 2022;45(8):1607-1609.

18. Xiao F, Gao M, Yang J, He L,WeiH. FAM172A Deletion May Enhance Hepatic Steatosis by Promoting ER Stress.DigDis Sci. 2021;66(9):3054-3061.

19. Ma JL, He LL, Li P, Jiang L,WeiHS. Prognosis of endotherapy versus splenectomy and devascularizationforvariceal bleeding in patients with hepatitis B-related cirrhosis. SurgEndosc.2021;35(6):2620-2628.

20. Yang J, He L, Gao M, XiaoF,Zhang F, Wang S, Shu Y, Ye X, Qu W, Li L, Wei H. Collagen β(1-O)galactosyltransferase2 deficiency contributes to lipodystrophy and aggravatesNAFLD related to HMWadiponectin in mice. Metabolism. 2021;120:154777.

21. He L, Ye X, Gao M, Yang J, MaJ,Xiao F, Wei H. Down-regulation of GLT25D1 inhibited collagen secretionandinvolved in liver fibrogenesis. Gene. 2020;729:144233.

22. Zhang X, Guo L, Zhang X, XuL,Tian Y, Fan Z, Wei H, Zhang J, Ren F. GLT25D2 Is Critical forInflammatoryImmune Response to Promote Acetaminophen-Induced Hepatotoxicity byAutophagyPathway. Front Pharmacol. 2020;11:01187.

23. Ma JL, He LL, Jiang Y, YangJR,Li P, Zang Y, Wei HS. New model predicting gastroesophageal varicesandvariceal hemorrhage in patients with chronic liver disease. Ann Hepatol.2020;19(3):287-294.

24. Hao X, Gao M, He L, Ye X,YangJ, Zhang F, Liu R, Wei H. Deficiency of O-linked-glycosylationregulatesactivation of T cells and aggravates Concanavalin A-induced liverinjury. Toxicology.2020;433-434:152411.

25. Ma JL, He LL, Li P, Jiang Y,HuJL, Zhou YL, Liang XX, Wei HS. Clinical Features and Outcomes ofRepeatedEndoscopic Therapy for Esophagogastric Variceal Hemorrhage inCirrhoticPatients: Ten-Year Real-World Analysis.Gastroenterol Res Pract.2020;2020:5747563.

26. Gao M, Li X, He L, Yang J, YeX,Xiao F, Wei H. Diammonium Glycyrrhizinate Mitigates Liver Injury ViaInhibitingProliferation Of NKT Cells And Promoting Proliferation Of Tregs. DrugDes DevelTher. 2019;13:3579-3589.

27. Zhao H, Wang Y, Liu Y, HaoX,Wei H, Xie W. The Effect of Protein FAM172A on Proliferation in HepG2 CellsandInvestigation of the Possible Molecular Mechanism. Anal Cell Pathol(Amst).2019;2019:5901083.

28. He L, Li P, Jiang Y, Hu J, MaJ,Ye X, Yang J, Zhou Y, Liang X, Ai Z, Lin Y, Wei H. A new algorithmforpredicting long-term survival in chronic hepatitis B patients withvaricealbleeding after endoscopic therapy. Dig Liver Dis. 2019;51(8):1166-1171.

29. He L, Ye X, Ma J, Li P, JiangY,Hu J, Yang J, Zhou Y, Liang X, Lin Y, Wei H. Antiviral therapyreducesrebleeding rate in patients with hepatitis B-related cirrhosis withacutevariceal bleeding after endotherapy. BMC Gastroenterol. 2019;19(1):101

30. Ma J, Li P, Jiang Y, Hu J,WeiH. Acute variceal bleeding in patients with primary myelofibrosissuccessfullytreated with endoscopic histoacryl injection. Turk J Gastroenterol.2018 Nov19. doi: 10.5152/tjg.2018.18324.

31. Hao X, Li Y, Wang J, Ma J,ZhaoS, Ye X, He L, Yang J, Gao M, Xiao F, Wei H. Deficient O-GlcNAcGlycosylationImpairs Regulatory T Cell Differentiation and Notch Signaling inAutoimmuneHepatitis. Front Immunol. 2018;9:2089.

32. Zhang MK, Ma HM, Zhang J,SongXC, Ye XH, Li YF, Zhang YF, He LL, Wei HS, Li X. Deletion of the C6orf120genewith unknown function ameliorates autoimmune hepatitis induced byconcanavalinA. Cell Immunol. 2018;331:9-15.

33. Jiang Y, Hu J, Li P, JiangW,Liang W, Wei H. A Retrospective Analysis of Cyanoacrylate InjectionversusHemoclip Placement for Bleeding Dieulafoy's Lesion in Duodenum.GastroenterolRes Pract. 2018;2018:3208690.

34. Hao X, Liu R, Zhang Y, Li Y,HeQ, Huang Y, Jiang Y, Ma J, Li P, Wei H. Glt25d2 Knockout DirectlyIncreasesCD25+CD69- but Decreases CD25-CD69+ Subset Proliferation and isInvolved inConcanavalin-Induced Hepatitis.  CellPhysiol Biochem.2018;50(3):1186-1200.

35. Ye X, He L, Ma J, Li Y, ZhangM,Yang J, Zhang J, Xiao F, Wei H. Downregulation of Glt25d1 aggravatescarbontetrachloride‑induced acute hepatic injury throughactivation of the TGF‑β1/Smad2signalingpathway. Mol Med Rep. 2018 Oct;18(4):3611-3618.

36. Yang Q, Wang J, Liu R, WangZ,Li Y, Zhang Y, Hao X, Huang Y, Xie W, Wei H. Amelioration ofconcanavalinA-induced autoimmune hepatitis by magnesium isoglycyrrhizinatethroughinhibition of CD4(+)CD25(-)CD69(+) subset proliferation. Drug Des DevelTher.2016;10:443-53.

37. Qiao Y, Chen J, Li X, WeiH,Xiao F, Chang L, Zhang R, Hao X, Wei H. Serum gp73 is also a biomarkerfordiagnosing cirrhosis in population with chronic HBV infection. ClinBiochem.2014;47(16-17):216-22.

38. Wei H, Zhang J, Li H, Ren H,HaoX, Huang Y. GP73, a new marker for diagnosing HBV-ACLF in populationwithchronic HBV infections. Diagn Microbiol Infect Dis. 2014;79(1):19-24.

39. Wei H, Li B, Zhang R, HaoX,Huang Y, Qiao Y, Hou J, Li X, Li X. Serum GP73, a marker forevaluatingprogression in patients with chronic HBV infections. PLoSOne.2013;8(2):e53862.

40. Fan X, Chuan S, Hongshan W.ProteinO glycosylation regulates activation of hepatic stellate cells.Inflammation.2013;36(6):1248-52.

41. Wei H, Hao X, Li B, Li X, HouJ,Qiao Y, Zhang R, Li X. GP73 is a potential marker for evaluatingAIDSprogression and antiretroviral therapy efficacy. Mol Biol Rep.2013;40(11):6397-405.

42. Wei HS, Wei HL, Zhao F,ZhongLP, Zhan YT. Glycosyltransferase GLT8D2 positively regulates ApoB100proteinexpression in hepatocytes. Int J Mol Sci. 2013;14(11):21435-46.

43. Fan X, Fang D, Bin D, XueyongL,Jun C, Hongshan W. Serum levels of surface large envelope proteins:prognosticmarkers for hepatitis B e antigen-negative patients with adefovirdipivoxiltreatment. Antivir Ther. 2009;14(8):1149-56.